Post-Marketing Surveillance of Tofacitinib in Japanese Patients with Rheumatoid Arthritis

Next Previous
Trial Profile

Post-Marketing Surveillance of Tofacitinib in Japanese Patients with Rheumatoid Arthritis

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs Tofacitinib (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions
  • Sponsors Pfizer

    • Most Recent Events

    • 08 Nov 2017 Results of the 6-month interim analysis (n=2882; Data cut-off: 4 Mar 2017) presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
    • 05 Jul 2017 New trial record
    • 17 Jun 2017 6 month interim analysis results (n=2387, data cut off: 5 Nov 2016) presented at the 18th Annual Congress of the European League Against Rheumatism
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top